Taysha Gene Therapies Inc [NASDAQ: TSHA] stock went on an upward path that rose over 46.63% on Tuesday, amounting to a one-week price increase of more than 88.19%.
Over the last 12 months, TSHA stock rose by 58.80%. The one-year Taysha Gene Therapies Inc stock forecast points to a potential upside of 62.71. The average equity rating for TSHA stock is currently 1.09, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $489.82 million, with 186.96 million shares outstanding and 158.49 million shares in the current float. Compared to the average trading volume of 2.21M shares, TSHA stock reached a trading volume of 24442337 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Taysha Gene Therapies Inc [TSHA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TSHA shares is $6.41 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TSHA stock is a recommendation set at 1.09. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Taysha Gene Therapies Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 27, 2024. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on April 09, 2024, representing the official price target for Taysha Gene Therapies Inc stock. Previously, the target price had yet another drop from $14 to $1.50, while Jefferies kept a Hold rating on TSHA stock. On January 27, 2023, analysts decreased their price target for TSHA shares from 23 to 3.
The Average True Range (ATR) for Taysha Gene Therapies Inc is set at 0.17, with the Price to Sales ratio for TSHA stock in the period of the last 12 months amounting to 38.06. The Price to Book ratio for the last quarter was 4.42, with the Price to Cash per share for the same quarter was set at 0.85.
TSHA Stock Performance Analysis:
Taysha Gene Therapies Inc [TSHA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 88.19. With this latest performance, TSHA shares gained by 20.10% in over the last four-week period, additionally sinking by -7.00% over the last 6 months – not to mention a rise of 58.80% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TSHA stock in for the last two-week period is set at 68.45, with the RSI for the last a single of trading hit 75.59, and the three-weeks RSI is set at 63.26 for Taysha Gene Therapies Inc [TSHA]. The present Moving Average for the last 50 days of trading for this stock 1.9700, while it was recorded at 1.6600 for the last single week of trading, and 2.3900 for the last 200 days.
Insight into Taysha Gene Therapies Inc Fundamentals:
Taysha Gene Therapies Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.20.
TSHA Stock EPS
With the latest financial reports released by the company, Taysha Gene Therapies Inc posted -0.93/share EPS, while the average EPS was predicted by analysts to be reported at -0.17/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.76. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TSHA.
Taysha Gene Therapies Inc [TSHA] Institutonal Ownership Details
There are presently around $78.21%, or 94.84%% of TSHA stock, in the hands of institutional investors. The top three institutional holders of TSHA stocks are: FMR LLC with ownership of 21.21 million shares, which is approximately 9.1722%. RTW INVESTMENTS, LP, holding 18.8 million shares of the stock with an approximate value of $$42.11 million in TSHA stocks shares; and RTW INVESTMENTS, LP, currently with $$41.78 million in TSHA stock with ownership which is approximately 8.0649%.
